Journal of Immunology Research / 2015 / Article / Fig 8

Research Article

The Role of Aggregates of Therapeutic Protein Products in Immunogenicity: An Evaluation by Mathematical Modeling

Figure 8

Aggregation could contribute to immunogenicity by inducing the presentation of high affinity epitopes that may not be present in nonaggregated TPP under a variety of drug doses. Simulated ADA production is shown for the same conditions as in Figure 7 for biweekly administered dose of 40 mg ((a), (e), and (i)), 4 mg ((b), (f), and (j)), 0.4 mg ((c), (g), and (k)), and 0.04 mg ((d), (h), and (l)). ADA production has the same definition as in Figure 4.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.